HRP20192111T1 - Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g - Google Patents
Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g Download PDFInfo
- Publication number
- HRP20192111T1 HRP20192111T1 HRP20192111TT HRP20192111T HRP20192111T1 HR P20192111 T1 HRP20192111 T1 HR P20192111T1 HR P20192111T T HRP20192111T T HR P20192111TT HR P20192111 T HRP20192111 T HR P20192111T HR P20192111 T1 HRP20192111 T1 HR P20192111T1
- Authority
- HR
- Croatia
- Prior art keywords
- accordance
- subject
- preparation according
- preparation
- human igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769673P | 2013-02-26 | 2013-02-26 | |
| US201361862814P | 2013-08-06 | 2013-08-06 | |
| PCT/US2014/018426 WO2014134070A1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
| EP14714815.9A EP2961426B1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192111T1 true HRP20192111T1 (hr) | 2020-03-20 |
Family
ID=50424697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192111TT HRP20192111T1 (hr) | 2013-02-26 | 2014-02-25 | Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9556260B2 (enExample) |
| EP (2) | EP2961426B1 (enExample) |
| JP (1) | JP6379113B2 (enExample) |
| AU (2) | AU2014223679B2 (enExample) |
| DK (1) | DK2961426T3 (enExample) |
| ES (1) | ES2759226T3 (enExample) |
| HR (1) | HRP20192111T1 (enExample) |
| HU (1) | HUE046752T2 (enExample) |
| LT (1) | LT2961426T (enExample) |
| PL (1) | PL2961426T3 (enExample) |
| PT (1) | PT2961426T (enExample) |
| SI (1) | SI2961426T1 (enExample) |
| WO (1) | WO2014134070A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
| EP3129013A1 (en) * | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CN110996912A (zh) | 2017-08-20 | 2020-04-10 | 福摩莱克斯医药创新有限公司 | 用于鼻内递送的干粉组合物 |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| EP4021409A2 (en) * | 2019-08-13 | 2022-07-06 | Altimmune Inc | Therapeutic agent effectiveness and its route of administration |
| US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| EP3991573A1 (de) * | 2020-11-03 | 2022-05-04 | Patrick Faber | Zusammensetzungen zur nasalen applikation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (enExample) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| AU693306B2 (en) | 1995-01-23 | 1998-06-25 | Direct-Haler A/S | An inhaler |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US20070254889A1 (en) * | 2001-04-23 | 2007-11-01 | Lee-Way Jin | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease |
| WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| MX2007010244A (es) | 2005-02-23 | 2008-03-10 | Johnson & Johnson | Administracion intranasal de agentes activos al sistema nervioso central. |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US8852585B2 (en) * | 2006-01-30 | 2014-10-07 | Grifols Therapeutics Inc. | Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM |
| MX2008010612A (es) * | 2006-02-15 | 2009-03-20 | Ramot At Tel Aviv University | Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro. |
| EP2152240A4 (en) | 2007-06-08 | 2012-05-09 | Healthpartners Res Foundation | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM |
| US8852874B2 (en) * | 2008-02-29 | 2014-10-07 | Baxter International Inc. | Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| US8772462B2 (en) * | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
-
2014
- 2014-02-25 WO PCT/US2014/018426 patent/WO2014134070A1/en not_active Ceased
- 2014-02-25 LT LTEP14714815.9T patent/LT2961426T/lt unknown
- 2014-02-25 ES ES14714815T patent/ES2759226T3/es active Active
- 2014-02-25 PL PL14714815T patent/PL2961426T3/pl unknown
- 2014-02-25 AU AU2014223679A patent/AU2014223679B2/en active Active
- 2014-02-25 SI SI201431417T patent/SI2961426T1/sl unknown
- 2014-02-25 US US14/189,981 patent/US9556260B2/en active Active
- 2014-02-25 DK DK14714815T patent/DK2961426T3/da active
- 2014-02-25 EP EP14714815.9A patent/EP2961426B1/en active Active
- 2014-02-25 HU HUE14714815A patent/HUE046752T2/hu unknown
- 2014-02-25 PT PT147148159T patent/PT2961426T/pt unknown
- 2014-02-25 HR HRP20192111TT patent/HRP20192111T1/hr unknown
- 2014-02-25 EP EP19197257.9A patent/EP3597220A1/en not_active Withdrawn
- 2014-02-25 JP JP2015559285A patent/JP6379113B2/ja active Active
-
2016
- 2016-10-26 US US15/335,027 patent/US10144776B2/en active Active
-
2018
- 2018-10-19 US US16/165,993 patent/US20190055307A1/en not_active Abandoned
- 2018-11-08 AU AU2018260883A patent/AU2018260883B2/en not_active Expired - Fee Related
-
2020
- 2020-12-14 US US17/121,553 patent/US11851481B2/en active Active
-
2023
- 2023-11-13 US US18/507,265 patent/US12503501B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2759226T3 (es) | 2020-05-08 |
| US10144776B2 (en) | 2018-12-04 |
| US12503501B2 (en) | 2025-12-23 |
| JP2016512490A (ja) | 2016-04-28 |
| AU2018260883B2 (en) | 2020-08-06 |
| US9556260B2 (en) | 2017-01-31 |
| LT2961426T (lt) | 2019-12-27 |
| EP3597220A1 (en) | 2020-01-22 |
| US20140242067A1 (en) | 2014-08-28 |
| US20240117025A1 (en) | 2024-04-11 |
| US20190055307A1 (en) | 2019-02-21 |
| DK2961426T3 (da) | 2019-12-02 |
| EP2961426B1 (en) | 2019-10-30 |
| SI2961426T1 (sl) | 2020-01-31 |
| PT2961426T (pt) | 2019-12-09 |
| WO2014134070A1 (en) | 2014-09-04 |
| PL2961426T3 (pl) | 2020-02-28 |
| AU2014223679B2 (en) | 2018-11-29 |
| EP2961426A1 (en) | 2016-01-06 |
| HUE046752T2 (hu) | 2020-03-30 |
| US20170044244A1 (en) | 2017-02-16 |
| US11851481B2 (en) | 2023-12-26 |
| US20210101967A1 (en) | 2021-04-08 |
| JP6379113B2 (ja) | 2018-08-22 |
| AU2014223679A1 (en) | 2015-09-24 |
| AU2018260883A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512490A5 (enExample) | ||
| CY1124546T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX2011012043A (es) | Sistema farmaceutico para suministro transmembrana. | |
| EA201491812A1 (ru) | Способ и система для введения легочного сурфактанта путем атомизации | |
| IN2014DN09377A (enExample) | ||
| JP6943994B2 (ja) | 神経精神系障害の治療のための組成物および方法 | |
| HRP20151214T1 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| JP2016501865A5 (enExample) | ||
| NZ606383A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| MX2014003186A (es) | Formulaciones farmacéuticas resistentes a la manipulación. | |
| WO2019136306A8 (en) | Intranasal delivery of levodopa powder by precision olfactory device | |
| ES2544840T3 (es) | Clenbuterol para su uso en el tratamiento del autismo | |
| RU2019118647A (ru) | Композиции с кариофилленом, устройства для их введения и способы их использования | |
| DE602008006700D1 (enExample) | ||
| IL318427A (en) | Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline | |
| MX2024014609A (es) | Composiciones y usos de nintedanib y de la combinacion de nintedanib en polvo seco | |
| CN105327349A (zh) | Nmda受体拮抗剂的医药用途及其药物组合物 | |
| JP2023518635A5 (enExample) | ||
| EA201590734A8 (ru) | Вдыхаемые лекарственные средства | |
| MX2021001227A (es) | Composicion que contiene un agente mucolitico para el tratamiento de hipersecrecion de moco y un dispositivo para su dosificacion. | |
| HRP20211197T1 (hr) | Rekombinantni glikoproteini i njihova uporaba | |
| RU2015119223A (ru) | Система дозированного распределения | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja |